​

Incyte (INCY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

INCY Stock Forecast

Incyte (INCY) stock forecast, based on 44 Wall Street analysts, predicts a 12-month average price target of $109.80, with a high of $140.00 and a low of $90.00. This represents a 1.83% increase from the last price of $107.83.

$50 $68 $86 $104 $122 $140 High: $140 Avg: $109.8 Low: $90 Last Closed Price: $107.83

INCY Stock Rating

Incyte stock's rating consensus is Buy, based on 44 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 23 Buy (52.27%), 19 Hold (43.18%), 2 Sell (4.55%), and 0 Strong Sell (0.00%).

Buy
Total 44 0 2 19 23 Strong Sell Sell Hold Buy Strong Buy

INCY Price Target Upside V Benchmarks

TypeNameUpside
StockIncyte1.83%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts4526
Avg Price Target$117.25$111.80$105.15
Last Closing Price$107.83$107.83$107.83
Upside/Downside8.74%3.68%-2.49%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2629151128
May, 2629131126
Apr, 2629121125
Mar, 26210122-26
Feb, 2629122-25
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 10, 2026Mitchell KapoorH.C. Wainwright$140.00$103.2335.62%29.83%
Jun 09, 2026Stephen WilleyStifel Nicolaus$123.00$103.0719.34%14.07%
Jun 08, 2026Jay OlsonOppenheimer$107.00$100.646.32%-0.77%
May 21, 2026Bernstein$99.00$97.411.63%-8.19%
Apr 29, 2026Oppenheimer$90.00$97.74-7.92%-16.54%
Feb 18, 2026Barclays$117.00$101.1615.66%8.50%
Feb 11, 2026Morgan Stanley$102.00$98.453.61%-5.41%
Feb 11, 2026Stephen WilleyStifel Nicolaus$120.00$100.0519.94%11.29%
Feb 06, 2026Allison BratzelPiper Sandler$110.00$102.767.05%2.01%
Feb 05, 2026H.C. Wainwright$135.00$102.6031.58%25.20%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 10, 2026H.C. WainwrightBuyBuyhold
Jun 09, 2026Cowen & Co.HoldHoldhold
Jun 08, 2026OppenheimerPerformPerformhold
Jun 08, 2026OppenheimerOutperformOutperformhold
Jun 02, 2026CitigroupMarket PerformMarket Performhold
May 21, 2026BernsteinMarket Performinitialise
May 21, 2026H.C. WainwrightBuyBuyhold
Apr 29, 2026OppenheimerPerformPerformhold
Mar 24, 2026BarclaysOverweightOverweighthold
Feb 06, 2026Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$0 $3 $6 $9 $12 $15 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.30$1.53$2.67$0.16$6.59---
Avg Forecast$2.58$1.76$3.60$1.26$5.90$7.18$8.78$10.69
High Forecast$2.76$1.86$3.70$1.53$6.91$9.31$11.60$11.43
Low Forecast$2.47$1.65$3.50$1.01$4.97$5.47$6.71$10.10
Surprise %66.67%-13.07%-25.83%-87.30%11.69%---

Revenue Forecast

$3B $3B $4B $5B $6B $7B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.99B$3.39B$3.70B$4.24B$5.14B---
Avg Forecast$2.92B$3.34B$3.69B$4.20B$4.64B$5.05B$5.46B$5.94B
High Forecast$3.08B$3.49B$3.73B$4.25B$4.89B$5.10B$5.52B$6.26B
Low Forecast$2.83B$3.18B$3.66B$4.13B$4.45B$5.01B$5.40B$5.70B
Surprise %2.12%1.69%0.18%0.87%10.90%---

Net Income Forecast

$0 $600M $1B $2B $2B $3B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$948.58M$340.66M$597.60M$32.62M$1.29B---
Avg Forecast$1.33B$1.45B$597.60M$287.16M$1.34B$1.26B$1.52B$2.41B
High Forecast$1.60B$1.74B$717.12M$345.89M$1.56B$2.10B$2.62B$2.58B
Low Forecast$1.07B$1.16B$478.08M$228.42M$1.12B$1.24B$1.52B$2.28B
Surprise %-28.88%-76.49%--88.64%-4.12%---

INCY Forecast FAQ

Is Incyte stock a buy?

Incyte stock has a consensus rating of Buy, based on 44 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 23 Buy, 19 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Incyte is a favorable investment for most analysts.

What is Incyte's price target?

Incyte's price target, set by 44 Wall Street analysts, averages $109.8 over the next 12 months. The price target range spans from $90 at the low end to $140 at the high end, suggesting a potential 1.83% change from the previous closing price of $107.83.

How does Incyte stock forecast compare to its benchmarks?

Incyte's stock forecast shows a 1.83% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Incyte over the past three months?

  • June 2026: 7.14% Strong Buy, 32.14% Buy, 53.57% Hold, 3.57% Sell, 3.57% Strong Sell.
  • May 2026: 7.69% Strong Buy, 34.62% Buy, 50.00% Hold, 3.85% Sell, 3.85% Strong Sell.
  • April 2026: 8.00% Strong Buy, 36.00% Buy, 48.00% Hold, 4.00% Sell, 4.00% Strong Sell.

What is Incyte’s EPS forecast?

Incyte's average annual EPS forecast for its fiscal year ending in December 2026 is $7.18, marking a 8.95% increase from the reported $6.59 in 2025. Estimates for the following years are $8.78 in 2027, and $10.69 in 2028.

What is Incyte’s revenue forecast?

Incyte's average annual revenue forecast for its fiscal year ending in December 2026 is $5.05B, reflecting a -1.69% decrease from the reported $5.14B in 2025. The forecast for 2027 is $5.46B, and $5.94B for 2028.

What is Incyte’s net income forecast?

Incyte's net income forecast for the fiscal year ending in December 2026 stands at $1.26B, representing a -2.14% decrease from the reported $1.29B in 2025. Projections indicate $1.52B in 2027, and $2.41B in 2028.